EA201691006A1 - Морфологические формы гексадецилоксипропиловых сложных эфиров фосфоновой кислоты и способы их синтеза - Google Patents

Морфологические формы гексадецилоксипропиловых сложных эфиров фосфоновой кислоты и способы их синтеза

Info

Publication number
EA201691006A1
EA201691006A1 EA201691006A EA201691006A EA201691006A1 EA 201691006 A1 EA201691006 A1 EA 201691006A1 EA 201691006 A EA201691006 A EA 201691006A EA 201691006 A EA201691006 A EA 201691006A EA 201691006 A1 EA201691006 A1 EA 201691006A1
Authority
EA
Eurasian Patent Office
Prior art keywords
synthesis
methods
hexadelecylopypropyl
morphological forms
complex ethers
Prior art date
Application number
EA201691006A
Other languages
English (en)
Other versions
EA031861B1 (ru
Inventor
Рой Уэнделл Уэр
Аарон Ли Дауни
Original Assignee
Чимерикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чимерикс Инк. filed Critical Чимерикс Инк.
Publication of EA201691006A1 publication Critical patent/EA201691006A1/ru
Publication of EA031861B1 publication Critical patent/EA031861B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)

Abstract

Изобретение описывает способы синтеза фосфонатных сложных эфиров. Способы в соответствии с изобретением обеспечивают возможность крупномасштабного получения фосфонатных сложных эфиров, имеющих высокую чистоту и высокую стабильность. Также описаны морфологические формы фосфонатных сложных эфиров.
EA201691006A 2013-11-15 2014-10-10 Морфологические формы гексадецилоксипропиловых сложных эфиров фосфоновой кислоты и способы их синтеза EA031861B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361904857P 2013-11-15 2013-11-15
PCT/US2014/060185 WO2015073148A1 (en) 2013-11-15 2014-10-10 Morphic forms of hexadecyloxypropyl-phosphonate esters

Publications (2)

Publication Number Publication Date
EA201691006A1 true EA201691006A1 (ru) 2017-02-28
EA031861B1 EA031861B1 (ru) 2019-03-29

Family

ID=52472937

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691006A EA031861B1 (ru) 2013-11-15 2014-10-10 Морфологические формы гексадецилоксипропиловых сложных эфиров фосфоновой кислоты и способы их синтеза

Country Status (15)

Country Link
US (7) US8962829B1 (ru)
EP (1) EP2999476B1 (ru)
JP (3) JP6150949B2 (ru)
KR (3) KR20170143009A (ru)
CN (2) CN111777639A (ru)
AU (3) AU2014349103B2 (ru)
BR (1) BR112016010862B1 (ru)
CA (1) CA2929593C (ru)
DK (1) DK2999476T3 (ru)
EA (1) EA031861B1 (ru)
ES (1) ES2685819T3 (ru)
IL (3) IL302520A (ru)
MX (1) MX362752B (ru)
UA (1) UA116825C2 (ru)
WO (1) WO2015073148A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013004925B1 (pt) * 2010-08-31 2020-09-29 Chimerix, Inc Formas mórficas do éster [[(s)-2-(4-amino-2-oxo-1(2h)-pirimidinil) -1-(hidroximetil)etóxi]metil] mono[3-(hexadecilóxi) propílico] do ácido fosfônico, composições farmacêuticas das mesmas, método para síntese e uso de uma forma mórfica b
SG10201800188SA (en) 2013-03-15 2018-02-27 Univ California Acyclic nucleoside phosphonate diesters
EA031861B1 (ru) * 2013-11-15 2019-03-29 Чимерикс Инк. Морфологические формы гексадецилоксипропиловых сложных эфиров фосфоновой кислоты и способы их синтеза
CN112898345A (zh) 2014-09-15 2021-06-04 加利福尼亚大学董事会 核苷酸类似物
WO2017048956A1 (en) 2015-09-15 2017-03-23 The Regents Of The University Of California Nucleotide analogs
JP6878473B2 (ja) * 2016-06-28 2021-05-26 キメリックス インコーポレイテッド ブリンシドフォビルの製剤
US20220135653A1 (en) * 2020-11-05 2022-05-05 Bravado Pharmaceuticals, LLC Intranasal Antiviral Therapy for Mucosal Protection Against Virus Infections

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002511A1 (en) 1990-08-10 1992-02-20 Bristol-Myers Squibb Company Novel process for the preparation of nucleotides
JP2002528461A (ja) * 1998-10-23 2002-09-03 ダーウィン・ディスカバリー・リミテッド 公知ペプチドメタロプロテイナーゼインヒビターの単一形態型
US6716825B2 (en) 1999-12-03 2004-04-06 The Regents Of The University Of California Phosphonate compounds
US20020022659A1 (en) * 2000-07-19 2002-02-21 Harris Gregory D. Crystalline and salt forms of an HIV protease inhibitor
WO2005030127A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2005087788A2 (en) 2004-03-04 2005-09-22 The Regents Of The University Of California Methods for preparation of nucleoside phosphonate esters
WO2006014429A2 (en) * 2004-07-02 2006-02-09 University Of Southern California (La) Cidofovir peptide conjugates as prodrugs
WO2006033848A1 (en) * 2004-09-15 2006-03-30 Merck & Co., Inc. Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
US7723338B2 (en) * 2005-01-31 2010-05-25 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4,7-dimethoxy-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-yl]-1,2-dioxoethyl]-piperazine
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
EP1865967A4 (en) 2005-04-08 2011-02-09 Chimerix Inc COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS AND OTHER DISEASES
EP1868628B1 (en) 2005-04-08 2014-06-11 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
GB0605344D0 (en) * 2006-03-17 2006-04-26 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
US7749983B2 (en) * 2006-05-03 2010-07-06 Chimerix, Inc. Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
WO2008007392A2 (en) * 2006-07-12 2008-01-17 Matrix Laboratories Limited Process for the preparation of tenofovir
WO2008084494A1 (en) * 2007-01-08 2008-07-17 Matrix Laboratories Limited Novel polymorphic forms of carvedilol dihydrogen phosphate and process for preparing the same
CN101678122A (zh) 2007-04-27 2010-03-24 奇默里克斯公司 在核苷给药的受体中降低肾中毒性的方法
ITMI20071594A1 (it) * 2007-08-02 2009-02-03 Solmag Spa Forma cristallina monoidrata di adefovir dipivoxil
CN101143879A (zh) * 2007-11-08 2008-03-19 上海交通大学 含硫无环核苷膦酸类似物及其制备方法
WO2009074351A2 (en) * 2007-12-12 2009-06-18 Ultimorphix Technologies B.V. Solid forms of tenofovir disoproxil
WO2011011519A1 (en) * 2009-07-21 2011-01-27 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
AU2010279678B2 (en) 2009-08-03 2015-09-10 Emergent Biodefense Operations Lansing Llc Composition and methods of treating viral infections and viral induced tumors
WO2011053812A1 (en) 2009-10-30 2011-05-05 Chimerix, Inc. Methods of treating viral associated diseases
AU2011216243B2 (en) * 2010-02-12 2015-07-09 Chimerix, Inc. Nucleoside phosphonate salts
US20110263536A1 (en) 2010-04-22 2011-10-27 Chimerix, Inc. Methods of Treating Orthopox Virus Infections and Associated Diseases
ES2691671T3 (es) * 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
BR112013004925B1 (pt) * 2010-08-31 2020-09-29 Chimerix, Inc Formas mórficas do éster [[(s)-2-(4-amino-2-oxo-1(2h)-pirimidinil) -1-(hidroximetil)etóxi]metil] mono[3-(hexadecilóxi) propílico] do ácido fosfônico, composições farmacêuticas das mesmas, método para síntese e uso de uma forma mórfica b
WO2013063436A1 (en) * 2011-10-26 2013-05-02 Chimerix, Inc. Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection
US20150087619A1 (en) * 2012-04-27 2015-03-26 Chimerix, Inc. Method of mitigating virus associated end-organ damage
WO2014008344A1 (en) * 2012-07-03 2014-01-09 Chimerix, Inc. Method of treating retroviral infections and related dosage regimes
EA031861B1 (ru) 2013-11-15 2019-03-29 Чимерикс Инк. Морфологические формы гексадецилоксипропиловых сложных эфиров фосфоновой кислоты и способы их синтеза
CN106061982A (zh) * 2013-12-05 2016-10-26 奇默里克斯公司 支链无环核苷膦酸酯及其合成方法与应用
JP6878473B2 (ja) * 2016-06-28 2021-05-26 キメリックス インコーポレイテッド ブリンシドフォビルの製剤

Also Published As

Publication number Publication date
BR112016010862A8 (pt) 2020-04-22
MX2016006241A (es) 2016-09-06
IL245576A0 (en) 2016-06-30
KR101812433B1 (ko) 2017-12-26
DK2999476T3 (en) 2018-09-03
US20200095208A1 (en) 2020-03-26
CA2929593A1 (en) 2015-05-21
BR112016010862A2 (pt) 2017-08-08
JP2017200920A (ja) 2017-11-09
CN111777639A (zh) 2020-10-16
IL245576B (en) 2022-03-01
US11912667B2 (en) 2024-02-27
AU2014349103B2 (en) 2017-01-12
US20160264531A1 (en) 2016-09-15
US20190016687A1 (en) 2019-01-17
US10112909B2 (en) 2018-10-30
JP2016538326A (ja) 2016-12-08
WO2015073148A1 (en) 2015-05-21
KR20170143010A (ko) 2017-12-28
EP2999476B1 (en) 2018-08-08
EP2999476A4 (en) 2016-04-13
US20150210724A1 (en) 2015-07-30
ES2685819T3 (es) 2018-10-11
AU2014349103A1 (en) 2016-06-16
AU2017203315A1 (en) 2017-06-08
EP2999476A1 (en) 2016-03-30
US8962829B1 (en) 2015-02-24
US20220144782A1 (en) 2022-05-12
JP2017200919A (ja) 2017-11-09
MX362752B (es) 2019-02-07
US9862687B2 (en) 2018-01-09
EA031861B1 (ru) 2019-03-29
BR112016010862B1 (pt) 2022-11-29
IL279291A (en) 2021-01-31
US10487061B2 (en) 2019-11-26
JP6150949B2 (ja) 2017-06-21
IL302520A (en) 2023-07-01
AU2017202386A1 (en) 2017-04-27
KR20160078500A (ko) 2016-07-04
UA116825C2 (uk) 2018-05-10
JP6401820B2 (ja) 2018-10-10
US20180086721A1 (en) 2018-03-29
US9371344B2 (en) 2016-06-21
CN105899215A (zh) 2016-08-24
KR20170143009A (ko) 2017-12-28
CA2929593C (en) 2020-03-10
US11066373B2 (en) 2021-07-20

Similar Documents

Publication Publication Date Title
EA201691006A1 (ru) Морфологические формы гексадецилоксипропиловых сложных эфиров фосфоновой кислоты и способы их синтеза
EA202092987A2 (ru) Липид, содержащий докозапентаеновую кислоту
CY1119105T1 (el) Παραγωγα διπυραζολιου ως αναστολεις jak
MY195167A (en) Modified Nucleotide Linkers
BR112015029933B8 (pt) Método de produção de tagatose
CO7141403A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
CO7141404A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
WO2014164533A8 (en) Methods of stereoselective synthesis of substituted nucleoside analogs
UY34472A (es) Derivados modificados de 4-fenil-piridina
EA201590629A1 (ru) Новые лиганды rig-i и способы их получения
CR20140534A (es) Proceso para la preparación de treprostinil y derivado de los mismos
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
UY34660A (es) Inhibidores de benzodioxano de la producción de leucotrieno
UA111333C2 (uk) Спосіб одержання l-аргінінової солі периндроприлу
EA201690793A1 (ru) Способ получения лиофилизированной фармацевтической композиции, содержащей митомицин c
CO7141402A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
IN2013MU01113A (ru)
MX2015009330A (es) Reordenamiento del virus de influenza.
DK2757162T3 (da) Fremgangsmåde til at øge udbyttet i fremstillingen af laktose (II)
BR112015017326A2 (pt) processo para a produção de 2-alquil-3-butin-2-óis
MX361673B (es) Procedimiento para la preparación de intermediarios de ácido borónico.
UY35715A (es) Proceso para preparar dronedarona y sales de la misma
MX364769B (es) Proceso para producir 2-fenil-1, 3-benzoxazoles.
IN2013MU02748A (ru)
IN2013MU03768A (ru)

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KZ